Page values for "Oxybutynin"
From Pharmacopedia
More actions
"Medicines" values
1 row is stored for this page| Field | Field type | Value |
|---|---|---|
| generic | String | Oxybutynin |
| brand | String | Ditropan, Ditropan XL, Oxytrol (transdermal), Gelnique (gel) |
| structure | File | |
| classes | List of String, delimiter: , | [[:Category:Antimuscarinics|Antimuscarinic]] • [[:Category:Overactive_bladder_medications|Overactive bladder medication]] |
| mechanism | String | |
| uses | String | '"`UNIQ--vote-000006DE-QINU`"', '"`UNIQ--vote-000006DF-QINU`"', '"`UNIQ--vote-000006E0-QINU`"' |
| starting_dose | String | IR 5 mg PO BID-TID; ER 5-10 mg PO daily, titrate; transdermal patch 3.9 mg/d twice weekly (OTC) |
| preparations | String | 5 mg IR tablets; 5, 10, 15 mg ER tablets; 5 mg/5 mL syrup; 3.9 mg/24 h transdermal patch (Oxytrol); 10% topical gel |
| fda_max | String | 30 mg/d (XL) typical |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral • transdermal • topical gel • intravesical |
| onset | String | 30-60 minutes (PO) |
| duration | String | IR: 6-10 hours; ER: 24 hours |
| halflife | String | 2-3 hours (parent and active N-desethyl metabolite)'"`UNIQ--ref-000006E1-QINU`"' |
| bioavailability | String | ~6% IR oral (substantial first-pass to active N-desethyl metabolite, which contributes most of the antimuscarinic adverse effects); transdermal bypasses first-pass and is better tolerated'"`UNIQ--ref-000006E2-QINU`"' |
| pregnancy | String | Limited data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> |
| legal | String | OTC (transdermal patch in women) and [[USLegal:Prescription only|Rx-only]] (other forms) in US |